Share this article on:

Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

Heitz, Florian MD*†; Amant, Frederic MD, PhD; Fotopoulou, Christina MD, PhD§; Battista, Marco J. MD; Wimberger, Pauline MD, PhD¶#; Traut, Alexander*†; Fisseler-Eckhoff, Annette MD, PhD**; Harter, Philipp MD*†; Vandenput, Ingrid MD; Sehouli, Jalid MD, PhD§; Schmidt, Marcus MD, PhD; Kimmig, Rainer MD, PhD; du Bois, Rabea*†; du Bois, Andreas MD, PhD*†

International Journal of Gynecological Cancer: January 2014 - Volume 24 - Issue 1 - p 54–60
doi: 10.1097/IGC.0000000000000019
Ovarian Cancer

Objectives This study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC).

Methods A retrospective case-control study including all patients with SEOC who had been treated at 5 European tertiary gynecologic oncology centers between 1996 and 2011 and patients with either EC or OC matched for age, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, year of diagnosis, and Eastern Cooperative Oncology Group performance score.

Results The study cohort comprised 77, 132, and 126 patients with SEOC, EC, and OC, respectively. The patient characteristics confirmed an equal distribution of matching factors, and the median follow-up did not differ (P = 0.44). 48.1% of the patients with SEOC showed early FIGO stage I for both EC and OC. The 5-year PFS rates differed between SEOC and EC (76.3% vs 86.3%; P = 0.047) but not the 5-year overall survival rates (71.6% vs 79.8%; P = 0.12) and did not differ between SEOC and OC (76.3% vs 63.8%; P = 0.19 and 71.6% vs 69.3%; P = 0.61, respectively). After the adjustment for the FIGO stage of the 2 components of SEOC, neither PFS nor overall survival rates were different.

Conclusions Prognosis of patients with SEOC tended to be the same in comparison with matched controls with either one EC or OC. Therefore, it could be considered that patients with SEOC may be eligible for clinical trials of the advanced tumor component if no additional therapy is indicated for the other component.

*Department of Gynecology and Gynecologic Oncology, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Kliniken Essen-Mitte, Essen; and †Department of Gynecology and Gynecologic Oncology, Dr. Horst-Schmidt Klinik, Wiesbaden, Germany; ‡Department of Gynecologic Oncology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven Belgium; §Department of Gynecology, Charité, Campus Virchow Clinic–University Hospital, Berlin; ∥Department of Gynecology and Obstetrics, Johannes-Gutenberg University Mainz, Mainz; ¶Department of Gynecology and Obstetrics, University of Duisburg–Essen, Essen; #Department of Gynecology and Obstetrics, Carl Gustav Carus University of Dresden, Dresden; and **Department of Pathology, Dr. Horst-Schmidt Kliniken, Wiesbaden, Germany.

Address correspondence and reprint requests to Florian Heitz, MD, Department of Gynecology and Gynecologic Oncology, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany. E-mail:

The authors declare no conflicts of interest.

Received July 1, 2013

Accepted September 10, 2013

© 2014 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.